Status:
COMPLETED
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Lead Sponsor:
Future University in Egypt
Conditions:
Peripheral Neuropathy Due to Chemotherapy
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, l...
Eligibility Criteria
Inclusion
- Females older than 18 years diagnosed with biopsy-confirmed breast cancer (Early breast cancer eligible for adjuvant or neoadjuvant) who are scheduled to receive paclitaxel 80 mg/m2.
Exclusion
- Known hypersensitivity to Losartan.
- Not Known Hypertensive patients
- Not Known Diabetic patients
- Treatment with Losartan/ARBs/ACE-I prior to the study.
- Previous neuropathy
- Renal impairment (Serum creatinine \> 2 mg/dl)
- Significant liver disease: liver enzymes 2 folds the upper normal limit
- Metastatic breast cancer
- Pregnancy or lactation
- Taking other medication for neuropathic pain
- Significant Hypotension
Key Trial Info
Start Date :
December 12 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2025
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT06135493
Start Date
December 12 2023
End Date
March 30 2025
Last Update
April 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Breast Cancer Comprehensive Center of the National Cancer Institute, Cairo University
Cairo, Egypt